Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Journal for ImmunoTherapy of Cancer · 2023-03 · 11 (3) · e004780
DOI: 10.1136/jitc-2022-004780 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 22.03.2023. Verfasst von Michael B Atkins und 19 weiteren Autor:innen. Beteiligte Einrichtung: Oncology, Georgetown University, Washington, District of Columbia, USA mba41@Georgetown.edu. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Soft Tissue Neoplasms, Sarcoma. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, U.S. Department of Defense, Bristol-Myers Squibb.
Abstract (Originalsprache)
Background
To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the efficacy of nivolumab/ipilimumab salvage therapy in patients with tumors unresponsive to initial nivolumab monotherapy.
Methods
Eligible patients with treatment-naïve nccRCC received nivolumab until progressive disease (PD), toxicity, or completion of 96 weeks of treatment (Part A). Patients with PD prior to, or stable disease (SD) at 48 weeks (prolonged SD) were potentially eligible to receive salvage nivolumab/ipilimumab (Part B). Patients were required to submit tissue from a metastatic lesion obtained within 12 months prior to study entry and prior to Part B for correlative studies.
Results
35 patients with nccRCC were enrolled: 19 (54%) had papillary, 6 (17%) had chromophobe and 10 (29%) had unclassified histology. At median follow-up of 22.9 months, RECIST-defined objective response rate (ORR) was 5 of 35 (14.3% 95% CI 4.8% to 30.3%) (complete response (CR) 2 (5.7%) and partial response (PR) 3 (8.6%)). ORR by histology was: papillary—1/19 (5%); chromophobe—1/6 (17%); and unclassified—3/10 (30%). Nine patients (26%) had tumors with sarcomatoid features with 3 (33%) (2 unclassified and 1 papillary) responding. ORR was 0/18, 3/11 (27%) and 2/6 (33%) for patients with tumor progammed death ligand 1 (PD-L1) expression of 3 treatment-related adverse events were seen in 7/35 (20%) on nivolumab and 7/17 (41%) on salvage nivolumab/ipilimumab with one patient experiencing sudden death.
Conclusions
Nivolumab monotherapy has limited activity in treatment-naïve nccRCC with most responses (4 of 5) seen in patients with sarcomatoid and/or unclassified tumors. Toxicity is consistent with prior nivolumab studies. Salvage treatment with nivolumab/ipilimumab was provided in half of these patients with minimal activity. Trial registration number NCT03117309 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology, Georgetown University, Washington, District of Columbia, USA mba41@Georgetown.edu.
- Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA.
- Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA.
- Oncology, Columbia University, New York, New York, USA.
ORCID-Profile: Michael B Atkins, Mehmet A Bilen, Moshe C Ornstein, David Braun
Förderung
- NCI NIH HHS
- U.S. Department of Defense
- Bristol-Myers Squibb
- National Cancer Institute
Zitieren
APA
Atkins, M. B., Jegede, O. A., Haas, N. B., McDermott, D. F., Bilen, M. A., Stein, M., Sosman, J. A., Alter, R., Plimack, E. R., Ornstein, M. C., Hurwitz, M., Peace, D. J., Signoretti, S., Denize, T., Cimadamore, A., Wu, C. J., Braun, D., Einstein, D., Catalano, P. J., & Hammers, H. (2023). Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for ImmunoTherapy of Cancer, 11(3), e004780. https://doi.org/10.1136/jitc-2022-004780
Vancouver
Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, et al. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for ImmunoTherapy of Cancer. 2023;11(3):e004780. doi:10.1136/jitc-2022-004780
BibTeX
@article{Atkins2023,
author = {Atkins, Michael B and Jegede, Opeyemi A and Haas, Naomi B and McDermott, David F and Bilen, Mehmet A and Stein, Mark and Sosman, Jeffrey A and Alter, Robert and Plimack, Elizabeth R and Ornstein, Moshe C and Hurwitz, Michael and Peace, David J and Signoretti, Sabina and Denize, Thomas and Cimadamore, Alessia and Wu, Catherine J and Braun, David and Einstein, David and Catalano, Paul J and Hammers, Hans},
title = {Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {3},
pages = {e004780},
doi = {10.1136/jitc-2022-004780}
}
EUVIMED